The 5 most recent market catalysts affecting $TSCN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 85
TScan Therapeutics shares are trading lower after HC Wainwright & Co. downgraded the stock from Buy to Neutral rating and lowered its price target from $7 to $1.
This headline represents a significant corporate catalyst for TScan Therapeutics. A downgrade from 'Buy' to 'Neutral' coupled with an 85% reduction in price target (from $7 to $1) …
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 95
TScan Therapeutics shares are trading lower after the company announced it paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital needed to complete the trial. Also, the company will reduce its workforce by 75%.
This is a major negative corporate catalyst for TScan Therapeutics. Halting a Phase 3 trial due to insufficient capital, coupled with a 75% workforce reduction, indicates severe fi…
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 55
TScan Therapeutics Announces About $4.1M In Employee-Related Charges From Strategic Reorganization, Expected To Be Substantially Complete By End Of Q4 2026
This headline indicates a corporate restructuring at TScan Therapeutics, involving employee-related charges. While $4.1 million is not a massive sum for a publicly traded company, …
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 75
TScan Therapeutics Announces Termination Of CFO Jason Amello And CMO Chrystal Louis Effective September 2; CEO Gavin MacBeath Assumes Principal Financial And Accounting Officer Duties
The simultaneous termination of a CFO and CMO at a biotechnology company like TScan Therapeutics is a significant corporate catalyst. It immediately raises red flags for investors …
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 95
TScan Therapeutics Announces Pause Of Enrollment In Phase 3 ALLOHA-2 Study Of TSC-101 Due To Insufficient Capital; Cuts Workforce About 75%, Extends Runway Into Q4 2027
This headline is a major negative catalyst for TScan Therapeutics (TSCN), indicating a critical failure in securing sufficient capital to continue a pivotal Phase 3 clinical trial.…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.